{
    "symbol": "HTGM",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-12 20:53:16",
    "content": "  Before we begin the call, let me remind you that the company's remarks include forward-looking statements within the meaning of the federal securities laws, including statements regarding our expected revenue build and momentum in 2022, our expectations regarding profiling revenue in future periods, our expectation that customers may use our HTP and whole transcript on miRNA panel for their studies as a result of the harmonized sample preparation protocol the importance of the company's HTG transcriptome panel statements related to the company's HTG Therapeutics and Drug Discovery business, the impacts of recent hires are planned white paper for specific drug discovery application, HTG becoming a disruptive hybrid life science drug discovery company, expected improvement in the coming quarters are future growth, business momentum and market opportunities and expected capabilities of our technology."
}